SG Americas Securities LLC Sells 6,229 Shares of Axonics, Inc. (NASDAQ:AXNX)

SG Americas Securities LLC lessened its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 74.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,092 shares of the company’s stock after selling 6,229 shares during the period. SG Americas Securities LLC’s holdings in Axonics were worth $146,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Headlands Technologies LLC lifted its position in Axonics by 31.1% during the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after buying an additional 265 shares in the last quarter. Whittier Trust Co. raised its stake in shares of Axonics by 59.1% in the first quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after acquiring an additional 424 shares during the last quarter. Xponance Inc. lifted its position in shares of Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after purchasing an additional 225 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Axonics during the first quarter valued at approximately $218,000. Finally, Mercer Global Advisors Inc. ADV increased its holdings in shares of Axonics by 12.7% in the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock valued at $469,000 after purchasing an additional 785 shares in the last quarter. Institutional investors own 99.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Axonics currently has an average rating of “Hold” and a consensus price target of $69.57.

Axonics Stock Performance

Shares of AXNX stock opened at $70.23 on Friday. The firm’s 50 day moving average price is $69.44 and its two-hundred day moving average price is $68.22. Axonics, Inc. has a 52-week low of $48.30 and a 52-week high of $70.53. The stock has a market cap of $3.58 billion, a PE ratio of -219.47 and a beta of 0.82.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. During the same quarter in the prior year, the business posted ($0.15) EPS. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, sell-side analysts predict that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Axonics

In other news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the transaction, the chief financial officer now directly owns 40,362 shares in the company, valued at approximately $2,801,526.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.85% of the company’s stock.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.